Clinical Trials
Enrolling Trials
121-130 of 169
Prescreen Failure (GYN) Data Repository Project
Data Repository - IRB Expedited Approval (SP# WEI30611). For reporting purposes only Prescreen Failure (Disease Team Site Specific) in VELOS was created. Each disease site is NOT a separate IRB approved study, all data is applicable under SP# WEI30611.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzDiagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
zzzMarshfield Clinic At James Beck Cancer Center
2251 NORTH SHORE DR
RHINELANDER, WI 54501
zzzMarshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI 54481
zzzMarshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI 54449
zzzMfld Clinic Cancer Care at Sacred Heart Hospita
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
zzzSacred Heart Hospital (Eau Claire)
900 W Clairemont Ave
Eau Claire, WI 54701
zzzSt. Clare's (Weston)
3400 Ministry Parkway
Weston, WI 54476
zzzSt. Mary's
2251 North Shore Drive
Rhinelander, WI 54501
zzzSt. Michaels Hospital
900 Illinois Ave
Stevens Point, WI 54481
Prescreen Failure (HEMATOLOGY) Data Repository Project
Data Repository - IRB Expedited Approval (SP# WEI30611). For reporting purposes only Prescreen Failure (Disease Team Site Specific) in VELOS was created. Each disease site is NOT a separate IRB approved study, all data is applicable under SP# WEI30611.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzDiagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
zzzMarshfield Clinic At James Beck Cancer Center
2251 NORTH SHORE DR
RHINELANDER, WI 54501
zzzMarshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI 54481
zzzMarshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI 54449
zzzMfld Clinic Cancer Care at Sacred Heart Hospita
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
zzzSacred Heart Hospital (Eau Claire)
900 W Clairemont Ave
Eau Claire, WI 54701
zzzSt. Clare's (Weston)
3400 Ministry Parkway
Weston, WI 54476
zzzSt. Mary's
2251 North Shore Drive
Rhinelander, WI 54501
zzzSt. Michaels Hospital
900 Illinois Ave
Stevens Point, WI 54481
Prescreen Failure (Melanoma) Data Repository Project
Data Repository - IRB Expedited Approval (SP# WEI30611). For reporting purposes only Prescreen Failure (Disease Team Site Specific) in VELOS was created. Each disease site is NOT a separate IRB approved study, all data is applicable under SP# WEI30611.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Prescreen Failure (MULTI-DISEASE) Data Repository Project
Data Repository - IRB Expedited Approval (SP# WEI30611). For reporting purposes only Prescreen Failure (Disease Team Site Specific) in VELOS was created. Each disease site is NOT a separate IRB approved study, all data is applicable under SP# WEI30611.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzDiagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
zzzMarshfield Clinic At James Beck Cancer Center
2251 NORTH SHORE DR
RHINELANDER, WI 54501
zzzMarshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI 54481
zzzMarshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI 54449
zzzMfld Clinic Cancer Care at Sacred Heart Hospita
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
zzzSacred Heart Hospital (Eau Claire)
900 W Clairemont Ave
Eau Claire, WI 54701
zzzSt. Clare's (Weston)
3400 Ministry Parkway
Weston, WI 54476
zzzSt. Mary's
2251 North Shore Drive
Rhinelander, WI 54501
zzzSt. Michaels Hospital
900 Illinois Ave
Stevens Point, WI 54481
Prescreen Failure (PEDIATRIC) Data Repository Project
Data Repository - IRB Expedited Approval (SP# WEI30611). For reporting purposes only Prescreen Failure (Disease Team Site Specific) in VELOS was created. Each disease site is NOT a separate IRB approved study, all data is applicable under SP# WEI30611. /ds
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzDiagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
zzzMarshfield Clinic At James Beck Cancer Center
2251 NORTH SHORE DR
RHINELANDER, WI 54501
zzzMarshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI 54481
zzzMarshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI 54449
zzzMfld Clinic Cancer Care at Sacred Heart Hospita
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
zzzSacred Heart Hospital (Eau Claire)
900 W Clairemont Ave
Eau Claire, WI 54701
zzzSt. Clare's (Weston)
3400 Ministry Parkway
Weston, WI 54476
zzzSt. Mary's
2251 North Shore Drive
Rhinelander, WI 54501
zzzSt. Michaels Hospital
900 Illinois Ave
Stevens Point, WI 54481
Prescreen Failure (Surgical Oncology) Data Repository Project
Data Repository - IRB Expedited Approval (SP# WEI30611). For reporting purposes only Prescreen Failure (Disease Team Site Specific) in VELOS was created. Each disease site is NOT a separate IRB approved study, all data is applicable under SP# WEI30611.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
PRIMARY OBJECTIVES: I. To compare the proportions of participants in the tomosynthesis mammography (TM) and digital mammography (DM) study arms experiencing the occurrence of an ?advanced? breast cancer at any time during a period of 4.5 years from randomization, including the period of active screening and a period of clinical follow-up after the last screen (T4). SECONDARY OBJECTIVES: I. To assess the potential effect of age, menopausal and hormonal status, breast density, and family cancer history on the primary endpoint difference between the two arms. II. To compare the diagnostic performance of TM and DM, as measured by the area under the receiver operating characteristic (ROC) curve (AUC), sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). III. To compare the recall rates and biopsy rates for TM versus DM, with subset analyses by the same variables as listed in aim II. IV. To compare the rate of interval cancers for TM and DM and to assess the mechanism of diagnosis for these interval cancers with categorization by symptomatic versus (vs) asymptomatic, and how detected: diagnosed via physical examination, mammography, ultrasound (US), magnetic resonance imaging (MRI) or other technologies. V. To examine the correlation between Breast Imaging Reporting and Data System (BIRADS) imaging features and histologic and genetic features, such as invasive ductal and invasive lobular histology, high grade, high stage at diagnosis, and aggressive genetic subtypes. VI. To assess different combinations of TM and synthesized 2 dimensional (2D) or DM in reader studies to assist in determining the optimum balance between diagnostic performance, radiation exposure and technique. VII. To estimate and compare breast-cancer-specific mortality between the two study arms. VIII. To estimate and compare the prevalence of breast cancer subtypes (luminal A, luminal B, HER2+, basal-like) low, medium or high proliferation via PAM50 proliferation signatures, and p53 mutant-like or wild-type-like according to a validated p53 dependent signature in the two arms, overall and stratified on whether cancers were detected through screening or as interval cancers, and whether cancers were invasive or in situ. IX. To classify histologically malignant (true positive cases) and benign lesions (false positive cases) as normal-like or tumor-like using the PAM50 gene expression assay subtype (luminal A, luminal B, HER2, basal-like,), and low, medium, or high proliferation according to PAM50 proliferation signatures, and p53 mutant-like or wild-type-like according to a validated p53-dependent signature. X. To assess the agreement between local and expert study pathologists for all breast lesions (benign and malignant) biopsied during the 4.5 years of screening with TM or DM. XI. To create a blood and buccal cell biobank for future biomarker and genetic testing. XII. To compare health care utilization (including cancer care received) and cost of an episode of breast cancer screening by TM versus DM, overall and within subsets. XIII. To implement a centralized quality control (QC) monitoring program for both 2D digital mammography (DM) and tomosynthesis (TM), which provides rapid feedback on image quality, using quantitative tools, taking advantage of the automated analysis of digital images. XIV. To assess temporal and site-to site variations in image quality, breast radiation dose, and other quality control parameters in TM vs. DM. XV. To refine and implement task-based measures of image quality to assess the effects of technical parameters, including machine type, and detector spatial and contrast resolution on measures of diagnostic accuracy for TM. XVI. To evaluate which QC tests are useful for determination of image quality and those that are predictive of device failure, in order to recommend an optimal QC program for TM. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients undergo bilateral screening DM with standard craniocaudal (CC) and mediolateral oblique (MLO) views at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal. ARM B: Patients undergo manufacturer-defined screening TM at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal. After completion of study, patients are followed up for at least 3- 8 years after study entry.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
qa notification study.
qatest
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
ICH-Long Term Extension Trial of Setmelanotide (RM-493) for Patients who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated with genetic defects upstream of the MC4 Receptor in the Leptin-Melanocortin Pathway
Nephrology
Child
The purpose of this protocol is to continue the assessment of setmelanotide treatment in patients who have successfully completed all critical study evaluations in a prior trial of setmelanotide for the treatment of obesity associated with genetic defects in the leptin-melanocortin pathway upstream of the MC4 receptor. The primary objectives of this extension trial are to explore the long-term safety and tolerability of setmelanotide for up to 5 years or until drug is otherwise available through authorized use.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Phase 3 trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alstrom syndrome (AS) Patients with Moderate to Severe Obesity
Nephrology
Adult
This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type (MC4R) agonist, for the treatment of obesity and hyperphagia in patients with Bardet Biedl syndrome (BBS) or Alstrom syndrome (AS).
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449